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Abstract 
Qing Chang, M.S. 
Department of Chemistry, April 2009 
University of Kansas 
 
 Glycosylation on proteins serve many biological roles and their heterogeneity can 
affect various biological functions.  The site occupancy of the glycans as well as their 
various glycoforms makes glycans unique to analyze due to the fact that the variation in 
structure is not based on a genomic code.  Glycosylation is a post-translational 
modification that provides diverse glycoforms.   
 Mass spectrometry has become a standard technique for characterizing the site 
occupancy and glycoforms that a protein exhibits.  Methodologies in characterization of 
glycopeptides often include a proteolytic digest followed by purification of the digested 
protein with liquid chromatography.  Mass spectrometers are sensitive to salts and buffer 
contents, thus a purification of the sample before analysis is vital for the detection of the 
sample. 
 The research presented herein studies the glycosylation coverage of two HIV-1 
envelope proteins.  The intention of this study is to determine the specific sites on the 
HIV-1 protein that are heavily masked/protected by glycans or are free of glycans, in 
order for future studies to correlate if exposed regions on the protein are favorable 
regions for vaccine design. 
 Another study was performed to aid in the glycosylation analysis of the HIV-1 
proteins.  Asialofetuin was used as a model protein to scrutinize the separation 
efficiencies of three various capillary columns.  Specifically the separation of 
glycopeptides from a peptide mixture was conducted on the three columns in order to 
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determine which platform would optimize the separation of N-linked HIV glycopeptides 
from a peptide mixture. 
 
 v
Table of Contents 
 
1.  Introduction into HIV-1 and Glycopeptide Analysis 
 
1.1   Introduction into Glycomics     1 
1.2   Types of Glycans       2 
1.3   Introduction into HIV and HIV glycoprotein    4 
 1.3.1   Synthesis of HIV in mammalian cells   5 
 1.3.2   Variation of HIV sequence    11 
 1.3.3   Methods for addressing HIV sequence variation  13 
1.4   Challenges for glycan analysis     14 
1.5   Experimental design required for glycopeptide analysis  15 
 1.5.1   Reduction and alkylation     16 
 1.5.2   Enzymes used for digestion of glycopeptides  17 
 1.5.3   N-Deglycosylation with PNGase F    18 
 1.5.4   Purification methods for glycopeptide analysis  18 
  1.5.4.1   Reverse-phase chromatographic separation  20 
  1.5.4.2   Reverse-phase chromatographic separation   21 
     with porous graphite carbon    
  1.5.4.3   Normal-phase chromatographic separation  24 
 1.5.5   Glycoform composition analysis in glycopeptides  26 
1.6   Mass spectrometry      31 
1.7   Electrospray ionization      32 
1.8   Fourier Transform Ion Cyclotron Resonance    33 
1.9   Matrix-Assisted Laser Desorption/Ionization with Time-of-Flight 36 
1.10   Detectors       36 
1.11   Other methods for glycopeptide analysis    37 
1.12   Overview and summary of each chapter    38 
1.13   References       42 
 
2.  Glycosylation Coverage of HIV-1 Envelope Proteins      
2.1   Introduction       46 
2.2   Experimental Design      49 
 2.2.1  Tryptic digest       50 
 2.2.2  Reverse-phase High Performance  
   Liquid Chromatography Fractionation    51 
 2.2.3  N-Deglycosylation      51 
 2.2.4  Matrix-Assisted Laser Desorption/Ionization     
   Time-of-Flight/Time-of-Flight Analysis    52 
 2.2.5  High Performance Liquid Chromatography/Electrospray Ionization   
   Fourier transform ion cyclotron resonance mass spectrometry analysis 52 
 2.2.6  Data Analysis       53 
2.3   Results and Discussion      55 
2.4   Conclusion       59 
2.5   References       60 
 
3.  Glycopeptide Separation Methods Using Asialofetuin 
3.1   Introduction       61 
3.2   Experimental Design      66 
 3.2.1   Protease Digestion     67 
 3.2.2   Glycopeptide Enrichment using capillary columns  68 
 3.2.3   Data Analysis      69 
3.3   Results and Discussion      71 
3.4   Conclusion       74 
3.5   References       75 
 vi
 




Introduction into HIV-1 and Glycopeptide Analysis 
1.1  Introduction in Glycomics 
 Glycomics is defined as the analysis of a whole set of glycans produced in a 
single organism.1  The study of glycomics is crucial because all living cells of all 
organisms bear glycans that are involved in many biological activities, such as cell 
development, differentiation or markers of cells types, morphogenesis, etc.2  Glycans 
have also shown to be important in viral infections.3   
 There are no known viruses that encode within their genome the ability to 
biosynthesize glycans on their own.4  Viruses are dependent on the host cell’s 
glycosylation machinery for the glycans that are attached to their proteins.4  The study 
of glycans present on viruses will lead to better understanding of viral infection and 
may lead to better treatment.   
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1.2  Types of Glycans 
 There are three types of glycosylation found on eukaryotic proteins (N-
glycosylation, O-glycosylation, and GPI-anchoring).1  This study focuses on N-
glycosylation because its predominance in mammalian cells,4 and particularly, its 
prevalence in HIV-1 Env proteins.  N-glycosylation has a glycan attached to a 
asparagine, and this is called asparagine-linked or N-linked.3  N-linked glycosylation 
occurs when glycans are attached to asparagine in a peptide chain containing a 
sequence Asn-X-Ser/Thr, where X is any amino acid except for proline.3, 5  
Glycosylation occurs in the endoplasmic reticulum (ER) and Golgi compartment.5  
Glycans that are not modified/processed through the ER and Golgi are called high 
mannose glycans.5  Glycans that are processed in the ER and Golgi are called hybrid 
and complex glycans.5  High mannose glycans have glycoforms that range from 5-9 
mannose sugars.7  Hybrid and complex glycans have glycoforms that have either 
three or more hexose (Hex) and four or more N-acetylglucosamine (HexNAc) or they 
have four or more hexose (Hex) and three or more N-acetylglucosamine (HexNAc).7  





Fig. 1.1:  N-linked glycoforms of both processed and unprocessed glycans 
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1.3  Introduction into HIV and HIV glycoproteins 
 Human immunodeficiency virus (HIV) infection is a pandemic that continues 
to increase at a rate of 14,000 new infections per day.6  It is transmitted through 
blood, sexual contact, and from mother-to-infant.6  HIV attacks a target cell by fusing 
the viral membrane with the plasma membrane of the target cell.7  The viral 
membrane contains viral envelope spikes composed of a 120,000 dalton exterior 
envelope glycoprotein (gp120) which was first synthesized as an 845 to 870 amino 
acid precursor in the rough endoplasmic reticulum (rough ER)7 and a 41,000 dalton 
transmembrane glycoprotein (gp41).7, 8  High-mannose sugar chains are then added to 
form the glycoprotein gp160.7  This polyprotein is transported to the Golgi apparatus 
to undergo glycosylation modification for proper folding and conformational 
stability.7, 9  Within the Golgi apparatus, gp160 is cleaved by furin or equivalent 
endoproteases to produce gp120 (the exterior envelope glycoprotein) and gp41 (the 
transmembrane glycoprotein).7, 9   
HIV initiates infection by targeting the CD4 molecule found on the surface of 
some CD4 T lymphocytes.10  Through direct fusion between the virus envelope and 
the cell membrane10, the gp120 first binds to CD4 to induce a conformational change 
that facilitates the binding of the co-receptor (CCR5 or CXCR4).  When gp120 binds 
to the co-receptor, it induces a change in gp41 that leads to the virus fusing with the 
host cell.11   
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1.3.1  Synthesis of HIV proteins in mammalian cells 
 HIV uses the host’s ER and Golgi to synthesize the glycans that attach to the 
Env protein.  The ER synthesizes proteins and allows for the transport of proteins 
through the cell.14  The majority of the synthesized proteins are glycoproteins.15  
When the N-linked glycans are first added to the polypeptide chains, they display a 
consensus “core glycan,” which is shown in Figure 1.2.12   
 
 
Fig. 1.2:  The consensus “core glycans” of mammalian species within the ER. 
 
 The core glycans were first synthesized within the cytosol of the ER 
membrane.12  Within mammalian cells, the core glycans were constructed as a 
membrane-bound dolichylpyrophosphate precursor by enzymes on both sides of the 
ER.13  Sugars are added one at a time within the cytosol.12  Two N-
acetylglucosamines and five mannoses are added to the dolichylphosphate.14  After 
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the addition of two N-acetyglucosamines and five mannoses, the oligosaccharide is 
placed on the lumen side of the ER membrane.13  Within the lumen, seven sugars are 
then added onto to form the “core glycans”.12   
 The core glycans synthesized in the ER consist of 14 saccharides.12  Once the 
core oligosaccharides are assembled, the oligosaccharyltransferase (OST) transfers 
the core glycans onto a growing polypeptide chain by adding the N-linked glycans to 
the side chain nitrogen of the Asn residue with an N-glycosidic bond.15  Every 
polypeptide that departs the translocon complex to the ER lumen has to be examined 
by the OST for the consensus sequence of Asn-X-Ser/Thr.16  Three glucoses are 
cleaved by glucosidase I and glucosidase II and the terminal mannose are cleaved by 




Fig. 1.3:  Modification of glycans within the ER. 
 
 Glucosidase I cleaves the α-1,2 linkage of the outermost glucose linked to the 
middle glucose.17  Glucosidase I in conjunction with glucosidase II prevent any 
binding of the protein-bound glycan to OST.17  The glycoprotein then folds and is 
transported to the Golgi complex.  The majority of proteins that fold in the ER gain 
disulfide bonds through oxidation process catalyzed by thiol-disulfide 
oxidoreductases.18  If the glycoproteins undergo incomplete or improper folding, they 
are degraded within the ER.18  The synthesized glycoproteins in the ER pass through 
the Golgi complex before leaving to their targeted functions.18   
 8
 Glycans are also altered thru the calnexin/calreticulin cycle.  Calnexin is a 
transmembrane protein and calreticulin is a soluble luminal ER protein.13  Both are 
monomeric, calcium-binding proteins, and have ER localization signals.19  
Glucosidase I removes the first glucose and glucosidase II removes the second 
glucose.13  The glycans that remain bind to calnexin or calreticulin.13  This prevents 
the glycoproteins being exported before proper modifications.13  The calnexin and 
calreticulin also protect any intermediates from premature degradation and also 
exposes them to a thiol-disulfide oxidoreductase, ERp57.19  The ERp57 is a cofactor 
that aids in proper disulfide bond formation.20  Glucosidase II releases the 
glycoprotein from calnexin and calreticulin.20  This allows for the glycoprotein to 
leave the ER.20   
 After the glycoprotein were released from the calnexin and calreticulin, they 
are free to leave the ER unless recognized by a soluble enzyme, UDP-
Glc:glycoprotein glucosyltransferase (GT).20, 21  GT is a large soluble protein that is 
located near the exit of the ER and in the ERGolgi intermediate compartment 
(ERGIC).21  GT targets incomplete folded glycoproteins for proper folding and 
oligomerization.19  It is not clear how GT senses which glycoprotein is incompletely 
folded.  One possibility is that protein may be able to sense if another protein is 
incompletely folded through exposed hydrophobic peptides and surface dynamics.21  
Studies have also shown that only glycopeptides with more than twelve amino acid 
residues and have hydrophobic residues on either the N-terminal side or C-terminal 
side will be recognized by GT if that glycoprotein was incompletely folded.19  Studies 
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have also shown that GT does not require interactions and will recognize incomplete 
folding with the absence of glycans.19   
 When glycoproteins fail to fold or oligomerize, they are retained in the ER.22  
The ER-associated degradation (ERAD) prevents accumulation of misfolded proteins 
in the ER.22  There are three steps in removal of misfolded proteins:  recognition of a 
misfolded glycoprotein, retrotranslocation to the cytoplasm, and the ubiquitin-
dependent degradation by the proteasome.22  Recognition of misfolded proteins is 
based on a timer mechanism.23  Degradation of misfolded proteins starts after a lag 
period of 30 to 90 minutes.23  This allows for folding intermediates to have enough 
time to properly fold inside the ER.23  This process is now well know, there may be 
other factors besides a timer delay.23  The delay in degradation of glycoproteins by 
ERAD is linked to the trimming of mannoses.24  The α-1,2 exomanosidase that 
removes the terminal mannose from the B branch is key in the timer mechanism.25  
Studies have show that if the mannosidase is inhibited by kifunensin, the degradation 
process is dramatically slower.26  If the mannosidae I is overexpressed, then the 
degradation is accelerated.26  The removal of mannose varies from 10 minutes in 
yeast cells to an hour in mammalian cells.26  This lag time varies for different 
proteins.26  The mannosidase is slow-acting to protect the newly synthesized 
proteins.26   
 Further modifications occur when the glycoproteins are transported to the 
Golgi complex.  The Golgi apparatus modifies proteins by adding and trimming 




Fig. 1.4:  Modifications of glycans within the Golgi Apparatus. 
 
 Sugars can be added during the terminal glycosylation stage to form complex 
N-linked glycans.14  The glycoproteins are modified as they move from the entry side 
(cis) to the exit side (trans).25  The average time that glycoproteins spent within the 
Golgi is usually between five to fifteen minutes.25   
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1.3.2  Variation of HIV Env protein sequence 
 The process of HIV infection is well known, yet developing a vaccine to 
prevent this infection is difficult, due to the protein’s high diversity in genetic 
sequence.  The diversity of HIV is characterized based on its many clades or 
subtypes.  These clades differ in their genetic sequence and are categorized by their 
geographic prevalence.27  HIV is broken down into human immunodeficiency virus 
type 1 (HIV-1) and human immunodeficiency virus type 2 (HIV-2).  HIV-1 and HIV-
2 are differentiated based on their genetic similarities to known simian 
immunodeficiency virus (SIV).28  HIV-1 has the closest genetic similarity with 
SIVcpz, isolated from the chimpanzee subspecies Pantroglodytes troglodytes in 
Central Africa.28, 29  HIV-2 has the closest genetic similarity with SIVsm, from sooty 
mangabeys in West Africa.28, 29  These diverse set of viruses that dominate the HIV 
pandemic belong to HIV-1 M or “main” group.17, 19  There are nine major clades 
within HIV-1 group M (A to D, F to H, J, and K).29  Clade C is the most prevalent 
virus that causes more than half of all HIV infections worldwide.30  Clade B virus is 
predominant in the United States and in Western Europe.27   
 Variation in sequence between different clades leads to immunological 
ambiguity during vaccine development.  Strains of the same subtype can differ up to 
20% in their envelope protein sequence, while strains of different subtypes can differ 
up to 35%.31  There are many differences between clade B and clade C.  Clade C is 
more variable, especially in the α2-helix in the C3 region, whereas clade B is more 
conserved in this region.32  Studies show that the α2-helix region (composed of 18 
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residues in gp120 numbered 335 to 352) is more exposed in clade C.32  The α2-helix 
region may be more antigenic in clade C because it is more exposed and therefore 
more susceptible to antibody attacks.32   
 An HIV vaccine must be capable of neutralizing different subtypes of the 
virus.  Currently, most studies have focused on HIV-1 clade B viruses.  Little is 
known about clade C viruses, yet they are the most prevalent subtype in the world.  
Few vaccine strategies focuses on the HIV-1 genetic variation.30  These strategies 
predominately utilizes HIV-1 immunogens that come from viruses selected based on 
availability and geographic representation.30   
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1.3.3  Methods for addressing HIV sequence variation 
 There are currently two methods for selecting vaccine strains that address high 
levels of HIV sequence variation.  The first method uses an isolate from one subtype 
selected based on their prevalence within a geographical region.31  Essentially, a 
vaccine would be designed using an Indian strain to be used in India and a South 
African strain would be used in South Africa.31  However, this method is limited by 
the scale of the epidemic within that region.31  Strains from one region that match 
closely with a different region would be viewed as outliers.  For instance, a strain 
such as IN101 from India matches more to African subtype C strains than African 
strains are to each other would not be used for developing vaccines in Africa since it 
is outside the geographical region.33  The second method uses a consensus sequence 
or an ancestral sequence to minimize HIV diversity.33  A consensus sequence is 
designed based on the most common amino acid in each position of the sequence.31  
An ancestral sequence is designed based on a phylogenetic tree that shows the genetic 
distances between potential vaccine strains.33  This method has advantages in 
producing vaccines that have the potential to elicit cross-reactive response and is 
more economically feasible than producing multiple vaccines based on country-
specific strains.31   
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1.4  Challenges for glycan analysis 
 While HIV sequence variation has its own challenges, analysis of glycans 
itself also has its unique set of challenges.  Glycans are synthesized in a different 
manner than genes and proteins.1  Glycoproteins of the same type may have small 
variations in the glycan units from each other.3  This variation is termed 
microheterogeneity.3  Studies on ovalbumin obtained from the eggs of the same hen 
have shown variation of glycan units from 6:5 to 5:2 ratios of mannose to N-
acetylglucosamine.22   
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1.5  Experimental design using mass spectrometry for glycopeptide analysis 
 Glycan composition after modifications within the ER and Golgi apparatus 
can be characterized using mass spectrometry.  There are two strategies for analyzing 
glycopeptides using mass spectrometry.  One strategy is to cleave the glycans off the 
protein using enzymatic or chemical methods and analyzing the glycans directly.34 
Another strategy is to obtain glycopeptides in a peptide mixture using a protease 
digestion.34  The second strategy is beneficial in gaining site-specific information of 
the glycan coverage of the protein.34 
 16
1.5.1  Reduction and alkylation 
 Glycosylated proteins are more susceptible to proteolytic enzymes when the 
protein’s tertiary structure is distrupted.35  Surfactants such as:  urea, guanidine 
hydrochloride, and sodium dodecylsulfate are often used as denaturing agents to 
improve the unfolding and solubility of the proteins.25  Dithiothreitol (DTT) and 
iodoacetamide (IAA) are often used as the reducing and alkylating reagents 
respectively.36  DTT is used to promote reductive unfolding by breaking the protein’s 
disulfide bonds.36  IAA is used to prevent oxidative folding by preventing the protein 
from binding to it’s native disulfide bonds.36 
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1.5.2  Enzymes used for digestion of glycopeptides 
 Trypsin was used for the protease digestion.  Trypsin is well-known for 
cleaving the C-terminal side of lysine (Lys) and arginine (Arg) unless these residues 
are followed by a proline.  Trypsin allows for the digestion of a protein into mixture 
of glycopeptides and peptides. 
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1.5.3  N-Deglycosylation with PNGase F 
 Site-occupancy of glycans on N-linked asparagine residue provides useful 
information on the glycan coverage of a protein.  Knowing the amino acid sequences 
of the protein that were open, or lacking glycans, may aid in vaccine development.  It 
is well-known that Protein N-glycosidase F (PNGase F) enzymatically releases N-
linked glycans and converts the asparagines residue to aspartic acid causing, an 
observed mass shift of 1 Da as shown in Fig. 1.5.   
 
 
Fig. 1.5:  N-Deglycosylation of N-linked glycans using PNGase F 
 
1.5.4  Purification methods for glycopeptide analysis 
 Glycopeptide analysis from a proteolytic digest is problematic due to the 
presence of peptides along with glycopeptides in the sample.  Peptides ionize better 
than glycopeptides and would suppress the signal intensity of the glycopeptides if 
both are present in the sample.34   
 A variety of methods have been proposed to isolate the glycopeptides within a 
peptide mixture.  Lectin-affinity chromatography can isolate glycoproteins with 
different carbohydrate types.1  Lectins are specific for a particular carbohydrate.  For 
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example, Con A is specific for mannose and wheat germ agglutinin (WGA) is 
specific for N-Acetylglucosamine.1  This method is useful if the glycoforms are 
known on the glycopeptides.  Analysis of glycopeptides with an unknown variety of 
glycoforms would be problematic for this method.  Affinity separation using cellulose 
or sepharose on glycopeptides from a peptide mixture is another possible approach. 
The affinity of the cellulose or sepharose is dependent on the hydrogen bonding 
between the hydroxyl group of carbohydrates on cellulose or sepharose and the 
glycopeptides.37  The hydrogen bonding is not capable of completely separating the 
glycopeptides from the peptides.28  High-performance anion-exchange (HPAE) 
chromatography with pulsed amperometric detection (PAD) has been used to separate 
oligosaccharides according to molecular size, sugar composition, and linkage of the 
monosaccharide units.38  This technique requires high concentrations of sodium 
hydroxide and sodium acetate and these salt solvents have to be removed for further 
analysis.39  
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1.5.4.1  Reverse-phase chromatographic separation 
 Reverse-Phase High Performance Liquid Chromatography (rp-HPLC) is the 
conventional method for separation of glycopeptides after enzymatic digestion.28  
Silanes that possess alky chains (mainly C18) are the standard stationary phase for 
reverse-phase separation.40  The stationary phase may also contain polar alky groups 
to increase the retention of polar compounds.40  Polar embedded or polar end-capped 
groups have been used to improve separation efficiencies of highly polar 
compounds.41  However, the presence of polar functional group on the polar-
embedded stationary phase reduces the hydrophobicity of the stationary phase.41  The 
polar end-capped phase displays similar hydrophobic retention as the conventional 
C18 columns.41   
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1.5.4.2  Reverse-phase chromatographic separation with porous graphite carbon 
 Porous graphitized carbon (PGC) exhibit properties similar to reverse-phased 
columns, but are able to retain more hydrophilic analytes and provide separation of 
structurally similar oligosaccharides.33   
 PGC is composed of flat sheets of hexagonally-arranged carbon atoms.42  
London dispersion interactions hold the individual sheets of carbon atoms together.35  
More specifically, the dipole-induced-dipole interactions between the carbon atoms in 
adjacent sheets hold the flat carbon sheets together.35   
 The retention mechanism for PGC is due to a combination of dispersive 
interactions or hydrophobic interactions and charge-induced interactions.36, 37  
London dispersive interactions (as well as dipole-dipole and hydrogen bonding) 
between the analytes and the eluents decrease the analytes’ retention on the graphite 
surface.35  Similar London dispersive interactions also occur between the analytes and 
the graphite surface, and the net effect between the analyte-eluent dispersive 
interaction and analyte-graphite surface interaction determines the retention of the 
analyte for the graphite surface.35, 38  Hydrophobic interactions between the analyte 
and the eluent will affect the retention for the graphite surface.  Repulsions between 
the hydrophilic eluent and non-polar segments of the analytes will cause retention of 
the analyte on the graphite surface.35, 37   
 Charge-induced interactions force polar groups on the analyte to be closer to 
the graphite surface, as shown in Fig 1.6.36, 38, 39  This is called PREG (polar retention 
effect on graphite).36, 38  The flat surface reduces the retention of highly structural and 
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rigid analytes, which can only come in contact with the graphite surface with a 
portion of their own surface.36, 38  The molecular area of an analyte that is in contact 
with the graphite surface largely determines the strength of the interaction.43  Hence, 
planar molecules tend to come in contact with the graphite surface better than non-
planar molecules, and they have a higher retention for the graphite surface than non-
polar molecules.42   
 
 
Fig. 1.6:  Charge-induced interactions from polar groups of the analyte 
 
 The PGC is preferred over reverse-phase columns for highly hydrophilic 
compounds.  In reverse-phase chromatography, the hydrophobic part of the analyte 
interacts with the hydrophobic stationary phase.41  With increasing polarity of the 
analytes, the interaction between the analyte and solvents dominates and reduces the 
retention of the stationary phase.34, 41   
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 The PGC can be used from pH 1 to 14 and are unaffected by acidic or alkaline 
conditions.41  This allows for a wider range of solvents than reverse-phase 
chromatography.34, 41   
 
 24
1.5.4.3  Normal-phase chromatographic separation 
 Zwitterionic hydrophilic interaction liquid chromatography (ZIC-HILIC) has 
been proposed as a tool to enrich N-linked glycopeptides in a peptide mixture.42  A 
ZIC-HILIC stationary phase is based on a grafted polymeric layer with 
sulfoalkylbetaine zwitterionic moieties of 3-sulfopropyldimethylalkylammonio inner 
salts as the functional groups.43  A silica-based sulfoalklbetaine zwitterionic phase is 
the least affected packing material with respect to changing pH compared to other 
HILIC packing such as:  bare silica, aminopropyl silica, and amide silica.44  The ZIC-
HILIC is based on a partitioning mechanism with electrostatic interactions from the 
sulfonic group and quaternary ammonium group shown in Fig. 1.7.43, 45   
 
 
Fig. 1.7:  Stationary phase of ZIC-HILIC with partitioning mechanism and electrostatic 
interactions with the analyte 
 
 The ZIC-HILIC stationary phase has a zero net charge due to the 1:1 ratio of 
quaternary ammonium and sulfonic acid group.43  The stationary phases are very 
hydrophilic and easily absorb or imbibe water.41  Having a very hydrophilic 
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stationary phase and a relatively hydrophobic mobile phase allows for the hydrophilic 
analytes to partition between the hydrophilic stationary phase and relatively 
hydrophobic bulk eluent.41, 43, 46  The order of elution is the opposite of reverse-phase 
chromatography; the hydrophilic compounds will be retained longer than 
hydrophobic compounds.43, 46  This makes HILIC an ideal tool for analysis of 
complex samples with poor retention towards reverse-phase chromatography. 
 Since the retention of compounds is based on polar interactions, the retention 
of glycopeptides tends to increase with an increase in the length of the glycans chains, 
and the elution position may provide a rough indication of the glycans size.47   
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1.5.5  Glycoform composition analysis in glycopeptides 
 Glycopeptide data analysis consists of identifying the peptide and 
carbohydrate portions of the glycopeptides.  FTICR-MS and MALDI-TOF were the 
instrumentation used for the glycopeptide data analysis in this thesis.  These 
techniques produced MS1 and MS2 data, and the CID experiments resulted in 
characteristic product ions of the glycan compositions.   
 Characteristic ions in the CID data, such as the Y1 ion [Peptide + 203 +H]+, 
which represents the peptide portion and an N-acetylhexosamine (HexNAc) attached 
at the N-linked asparagine.  The Y1 ion is shown in Fig. 1.8.   
 
 
Fig. 1.8:  Characteristic Y1 ion found in CID spectrum 
 
 The Y1 ion that resulted from the fragmentation of the glycopeptides are used 
to assign glycopeptide peaks from the MS data.44  Each peak in the MS1 spectrum that 
may potentially correspond to a glycopeptide is the combination of the peptide and 
carbohydrate portions.  The m/z of each peak is the sum of the peptide and 
carbohydrates.  This leads to challenges of knowing how much the peptide mass and 
the carbohydrate mass contribute to each m/z of each peak.  It becomes time 
consuming to manually assign each peak, without knowing how much contribution 
the peptide mass or the carbohydrate mass has on the m/z of that peak.  A need for 
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software to account for these challenges greatly facilitates assigning the glycopeptide 
composition.   
 The glycopeptide compositions in this work were assigned using two web-
based programs:  GlycoPep ID44 and GlycoPep DB45.  GlycoPep ID aids in 
identifying the peptide portion of the glycopeptides.44  GlycoPep DB aids in 
identifying the glycan portion of the glycopeptides.45  Both web-based programs were 
implemented based on their advantage over other methods.  GlycoPep ID is capable 
of assigning the peptide portions when the proteolytic digest cleaves in a nonspecific 
manner.44  GlycoPep DB only assigns carbohydrates that have been found in 
nature/literature.45   
 The methodology for the data analysis of glycopeptides using GlycoPep ID 
and GlycoPep DB is shown in Fig. 1.9.48, 49  To use GlycoPep ID, the user inputs 
several parameters required to identify the peptide portion.  The user inputs the 
protein sequence, the specific enzyme used during the digestion experiment, cysteine 
modification, charge state, and mass tolerance.44   
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Fig. 1.9:  Overview of glycopeptide analysis with GlycoPep ID and GlycoPep DB 
 
 The user also inputs the peak list from the MS2 data.44  GlycoPep ID is able to 
calculate for the characteristic Y1 ion that occurs in MS2 experiments.44   
 In order to determine the peptide portion of the glycopeptide, GlycoPep ID 
first uses the input data to determine all the possible peptides with  N-linked 
glycosylation sites.44  A table of all possible peptides is generated, with the 
glycosylation sites.  This table lists all possible theoretical peptides that can occur 
with the specific digestion methods selected; this list of peptide masses is then 
compared to the experimental peak list from the MS2 data.44  The program matches 
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characteristic ions that fall within the mass tolerance specified by the user.44  If the 
program matches more than one peptide, the user can repeat the search with a 
different characteristic ion or look manually at the spectrum to confirm which peptide 
portion is correct.  Alternatively, both peptide possibilities could be considered in the 
next step, which is to determine the glycan portion using GlycoPep DB.   
 GlycoPep DB contains a database of 319 N-linked glycans that have been 
found in the literature.45  GlycoPep DB only uses biologically relevant glycans in 
assigning the carbohydrate portion of the glycopeptides.45  The user inputs the 
possible peptide sequence that is generated from GlycoPep ID, the charge state, the 
cysteine modification, any variable modifications from other amino acid residues, the 
charge carriers, the mass tolerance, and the experimental peak list.45  The user also 
selects for a particular database of biologically relevant glycans to match their 
experimental peak list from the high resolution MS1 experiment.45  GlycoPep DB 
generates a list of possible glycopeptide compositions that fall within the range of the 
mass tolerance.45   
 The following is a summary of the data analysis process:  First, the user can 
look at the lower mass range of an MS2 spectrum for characteristic fragmentation 
product ions shown in Fig. 1.10.  m/z 528 [HexNAc + 2Hex + H]+ , m/z 690 [HexNAc 
+3Hex + H]+, m/z 893 [2HexNAc + 3Hex + H]+, and m/z 657 [HexNAc + Hex + 




Fig. 1.10:  Characteristic fragmentation product ions of glycopeptides 
 
 If these are present, this indicates the spectrum is a glycopeptide.  The user 
can then input the MS2 peak list that contains any of those characteristic 
fragmentation product ions into GlycoPep ID to assign the peptide portion of the 
glycopeptides.34  The peptide that resulted from the GlycoPep ID assignment is then 
imputed into GlycoPep DB as well as the MS1 peak list to generate a list of possible 
glycan compositions.34  Once the plausible glycopeptide compositions have been 
generated using both GlycoPep ID and GlycoPep DB, the user can confirm those 
assignments by manually checking the MS2 spectra for all of the peaks that have MS2 
data by looking for cleavages of neutral losses of individual sugars and cleavages 
along the peptide backbone.   
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1.6  Mass spectrometry 
 Since glycan composition after modifications within the ER and Golgi 
apparatus is characterized using mass spectrometry, a short review of mass 
spectrometry is provided here.  Mass spectrometry (MS) is composed of three 
fundamental parts:  ion source, mass analyzer, and detector.  The ion source allows 
for the conversion of analytes to ions.46  The ions are separated based on their m/z in 
the mass analyzer.46  The detector converts the ions into electrical signals.46   
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1.7  Electrospray ionization 
 Electrospray ionization (ESI) was used on the HIV Env and alpha(1)-acid 
glycoprotein (AGP).  ESI converts a liquid sample into a gaseous sample.46  It 
generates charged droplets within an electrical field.46  Solvent from the charged 
droplets start to evaporate when heat, dry gas, or both are applied to the charged 
droplets in atmospheric pressure.46  Ions are created from the charged droplets when 
the Coulombic repulsion force reaches a point where the charge density on the 
surface exceeds the decreasing surface tension the charged droplets (Fig. 1.11).46  The 
charged molecules on the surface of the ions under a strong electric field causes the 
desorption of the ions.47  The sensitivity increases with higher concentration of 
charged molecules on the surface of the droplets.47   
 
 
Fig. 1.11:  Coulombic repulsion forces of ions created from charged droplets.  When the charge 




1.8  Fourier Transform Ion Cyclotron Resonance 
 Fourier transform mass spectrometry (FTMS) was first introduced by 
Comisarow and Marshall in 1974.47  FTMS is an ion trapping instrument that 
employs an analyzer cell to store and detect ions.48  The cubic analyzer cell is a 
commonly used analyzer cell and is shown in Fig. 1.12.49  Ions are excited by 
applying sinusoidal voltage to the emitter plate.48  The sinsoidal voltage or 
radiofrequency voltage creates an electric field where ions that are in resonance with 
the radiofrequency electric field will spiral outwards until they strike the detection 
plate or receiver plate.48, 49  Ions that are not in resonance with the radiofrequency 
electric field will remain at the center of the cubic cell.48, 49   
 
 
Fig. 1.12:  Depiction of a typical FT-ICR cell.  Ions within the cell are excited by the emitter plate 
and have different characteristic cyclotronic frequencies, depending on their mass.  This gives 
them a unique image current, which is detected by the receiver plate.   
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 Ions with the same mass-to-charge ratio undergo a cyclotron motion and are 
excited coherently.48  The cyclotron motion is described by Newton’s Second Law of 
Motion, which states that the force of an object is equal to the mass of the object 
times its acceleration.  Trajectories of ions in a spatially uniform magnetic field (B) 
are curved by the magnetic field.47  The moving ions are subject to a force with m as 
the ionic mass, q as the charge, and V as the velocity described in Eq. (1).49   
BqVdtdVm ×=⋅=⋅= /onacceleratimassForce   (1) 
 The trajectory of the ion is curved due to the magnetic field perpendicular to 
its original trajectory.  Hence, the force is equal to the charge multiplied by the 
velocity times the vector cross product of the magnetic field.49  Angular acceleration 
dtdV /  are affected by the magnetic field bending the ion path into a circle with a 
radius r  and changes with the ion’s velocity v  which is described in Eq. (2)49   
rVdtdV // 2=   (2) 
 The force is described by replacing Eq. (2) into Eq. (1) shown in Eq. (3). 
qBrmVqVBrmV == /)(or  /)( 2   (3) 
 The angular velocity ω  is described in Eq. (4) with a r⋅π2 as its circular 
trajectory with a frequency v .   
rVv /2 == πω   (4) 
Plugging Eq. (4) into Eq. (3) gives Eq. (5), which shows the angular velocity is 
independent of the velocity of the ion.49   
rqBrm ωω =2   (5) 
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Bmq )/(=ω   (5a) 
 A pulsed radio frequency is used to excite all of the ions orbiting in a magnet 
field.46  Ions with different masses have different characteristic cyclotronic 
frequencies.47  All ions are simultaneously accelerated giving each m/z a unique 
image current.46  The image current is Fourier-transformed to a frequency-dependent 
intensity corresponding to the ion’s m/z.46, 47   
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1.9  Matrix-Assisted Laser Desorption/Ionization with Time-of-Flight 
 Matrix-assisted laser desorption/ionization (MALDI) was created by Tanaka, 
Karas, and Hillenkamp in 1988.46  An organic molecule in solution such as 2,5-
Dihydroxybenzoic acid (DHB) is used as the matrix and the analyte is mixed with the 
matrix.47  An UV laser pulse causes the ionization of the matrix along with ionization 
of the analyte and transfer of it into the gas phase.46  The matrix absorbs most of the 
energy from the laser pulse to reduce sample damage.46  The matrix has an absorption 
that matches the laser frequency.47  Analytes with a variety of molecular weights 
including those exceeding 100,000 Da can be ionized using MALDI.47  Typically, 
MALDI observes singly charged molecular species.47   
The time-of-flight mass spectrometer uses a reflectron to increase the 
resolution, by increasing the amount of time for ions to reach the detector.46  The 
reflectron creates a retarding field and deflects the ions back through the flight tube.47  
Ions that have the same m/z but different kinetic energies will reach the detector at the 
same time.46, 47   
1.10  Detectors 
 Electron multipliers are the most common type of detectors.  They generate 
the emission of multiple secondary particles, as shown in Fig. 1.13.47  Electron 
multipliers are a series of dynodes with increasing potential.46  Ions that strike the 
first dynode emit electrons.46  The electrons are attracted to the next higher potential 




Fig.1.13  Depiction of a typical electron multiplier.  A cascade of electrons is produced from a 
series of dynodes at increasing potentials.   
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1.11  Other methods for glycopeptide analysis 
 There are three alternative approaches to determine glycan composition on a 
glycopeptide.  The first approach is an instrumental method, to use mass spectrometry 
to characterize glycans.1  This approach has already been covered in this chapter.   
 The second approach is centers around differences in chemical interactions, 
using 2-D/3-D mapping to characterize the chemical properties such as:  charge, 
molecular size, and hydrophobicity.1  Takahashi and coworkers have developed a 2-
D/3-D mapping using anion-exchange, normal-phase, and reverse-phase 
chromatography of pyridylaminated derivatives-oligosaccharides.50  Reducing ends of 
glycans are labeled with 2-aminopyridine as a fluorophore.50  The glycan elution data 
from the three different columns are places as separate axes to produce a three-
dimensional glycan mapping.39  Disadvantages of this method include time-
consuming experiments (over 80 mins per analysis) and lack of reproducible data.1   
 The third approach is a biochemical approach, using frontal affinity 
chromatography (FAC) to determine dissociation constants (Kd) or association 
constants (Ka) between two biomolecules.1  FAC works by placing excess volume of 
an analyte into a column with an immobilized affinity ligand.1  The initial 
concentration of the analyte is known and if the analyte has any affinity for the 
immobilized ligand, the elution of the analyte would be retarded and the difference 
would reflect the affinity of the analyte to the immobilized ligand.1  Disadvantages of 
this technique include requiring a large amount of the analyte for this analysis, and 
this method does not detect any glycans that are not recognized by any lectins.1   
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1.12  Overview and summary of each chapter 
 There were two main studies presented in this research.  The overall purpose 
of these studies was to characterize the glycoforms present on two different HIV-1 
envelope proteins and to determine their glycosylation coverage.  The first study was 
to characterize the glycoforms and site occupancy of N-linked glycopeptides on two 
clade C HIV-1 envelope proteins.  The second study was to identify a separation 
method corresponding to improving the identification of glycoforms for the HIV 
study.  Both studies used chromatography and mass spectrometry as the analytical 
techniques to procure the data needed for the glycosylation analysis.   
Chapter 2 
 Glycosylation on proteins impacts a variety of biological and cellular 
processes.  They are involved in processes such as:  cell development, 
morphogenesis, tumor metastasis, infection, etc.2  Glycans on a viral glycoprotein 
assist in various viral infections.51  The location of glycans on a viral glycoprotein can 
also affect the efficiency of a viral infection.4  Roughly fifty percent mass of the HIV-
1 envelope protein is contributed by the glycans.4  It has been well established that 
glycans play a significant role in concealing and assisting HIV in escaping 
neutralizing antibodies.4 
 The design of this study was to determine the glycosylation coverage on the 
two clade C HIV-1 envelope proteins.  Having a better understanding of the types of 
glycoforms and the locations of those glycoforms on the HIV-1 envelope protein may 
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assist future research in developing a neutralizing antibody to target the susceptible 
glycosylation regions. 
 Proteolytic digest of Con C and VRC_C were analyzed with MALDI-TOF 
MS and HPLC/ESI-FTICR MS to ascertain the glycosylation coverage on the two 
clade C HIV-1 envelope proteins.  The determination from both mass spectrometers 
revealed predominately high-mannose glycoforms throughout the glycosylation 
coverage of both clade C envelope proteins.  Complex and hybrid glycoforms were 
rarely seen throughout the glycosylation coverage.  This may be due to the separation 
efficiencies of the C18 column to elute glycopeptides from a peptide mixture.   
Chapter 3 
 Reverse-phased chromatography is the standard separation technique used for 
carbohydrate analysis.  A model experiment was designed to inspect the separation 
efficiencies of glycopeptides from a peptide mixture with various columns (Aquasil 
C18, Hypercarb, and ZIC-HILIC) each with its unique retention mechanisms.  
Asialofetuin was used as the model protein because its glycosylation sites have been 
well characterized with mass spectrometry.52  The intent of this study was to analyze 
the N-linked glycosylation sites on asialofetuin and differentiate which unique 
retention mechanism was the most desirable in separating glycopeptides from a 
peptide mixture, in order to improve the glycopeptides coverage for HIV-1 
glycopeptides.   
 A proteolytic digest, similar to the HIV-1 digest, was accomplished on 
asialofetuin.  The proteolyic glycopeptides were detected using HPLC/ESI-FTICR 
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MS, this approach does not require a rp-HPLC fractionation step, which would be 
necessary if MALDI-TOF MS was selected as the mass spectrometer.  The ZIC-
HILIC column was the only column to separate all three N-linked glycoforms on 
asialofetuin.   
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Glycosylation Coverage of HIV-1 Envelope Proteins 
2.1  Introduction 
 Carbohydrates play an important role in HIV’s ability to resist neutralization.1  
In addition, different strains of HIV-Env likely have different carbohydrate profiles.  
Information about variations in the carbohydrates among different HIV strains is 
needed for vaccine development.  Few studies have analyzed glycosylation on clade 
C strains.  Here, we look at the glycosylation of two different clade C strains (Con C 
and VRC_C) in the hopes that this will improve immunogenicity studies, by 
investigating how HIV uses different carbohydrates to defend against neutralization. 
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 The work presented herein focuses on comparing the glycosylation on a 
consensus (Con C) glycoprotein with a wild-type (VRC_C) glycoprotein and 
analyzing trends between their glycosylation patterns using mass spectrometry.  By 
identifying similarly conserved glycosylation patterns between a consensus clade C 
strain and a wild-type clade C strain, vaccine strategies can be further improved upon.   
 Con C Env sequences were synthesized from the 2001 Los Alamos HIV-1 
sequence database.  Con C was constructed using the most common amino acid at 
each position in the protein alignment.2, 3  For the hypervariable regions, only the 
minimal lengths of consensus were retained.2, 3  The VRC_C Env sequence is a wild-
type clade C strain that has retained the wild-type variable loop sequences and was 
used for comparison with Con C.  Both proteins were expressed in 293T cells by 
collaborators at Duke University Human Vaccine Institute. 
 There are potentially 29 N-linked glycosylation sites on Con C and 24 








Fig.  2.2  Sequence of VRC_C.  The N-linked glycosylation sites are in red. 
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2.2  Experimental Design 
 Con C and VRC_C proteins were expressed and purified from the Duke 
Human Vaccine Research Institute in Durham, NC.4  Ammonium bicarbonate 
(NH4HCO3), trizma hydrochloride, trizma base, urea, ethylenediaminetetraacetic acid 
(EDTA), dithiothreitol (DTT), iodoacetamide (IAA), HPLC grade acetonitrile (ACN), 
formic acid, 2,5-dihydroxybenzoic acid (DHB), and α-cyano-4-hydroxycinnamic acid 
(CHCA) were all purchased from Sigma-Aldrich (St. Louis, MO).  Proteomics grade 
trypsin was purchased from Promega (Madison, WI).  N-Glycosidase F (PNGase F) 
was acquired from Elizabethkingia meningosepticum and purchased from 
CalBioChem (San Diego, CA).  Purified water was obtained using a Millipore Direct-
Q3 Water Purification System (Billerica, MA).   
 The overall experiment is shown in Fig. 2.3 with explanations in the 
proceeding paragraphs.   
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Fig. 2.3:  Experimental design of the HIV-1 envelope glycopeptide analysis 
 
2.2.1  Tryptic Digestion 
 The HIV-1 Env proteins (Con-C and VRC_C) were subjected to a proteolytic 
digest.  Approximately 300 μg of the HIV-1 Env proteins were denatured with 6 M 
urea in 100 mM Tris-HCL buffer at a pH of 7.5 with 3 mM EDTA.  The proteins 
were reduced with 15 mM DTT for 1 hour and alkylated in the dark with 40 mM IAA 
for 1 hour, both at room temperature.  The sample was brought to a final 
concentration of 50 mM DTT to neutralize any excess IAA.  The proteins were 
digested with trypsin at a protein/enzyme ratio of 30:1 (wt/wt) in 37 °C for 18 hours.  
This was followed by a further addition of trypsin at the same protein/enzyme ratio 
and temperature.  The second trypsin addition was allowed to digest for 4 hours and 
was quenched by adding 1 μL of acetic acid for every 100 μL of total solution.  The 
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digested proteins were analyzed either online using HPLC/ESI-FTICR-MS or offline, 
using HPLC fractionation with MALDI TOF/TOF MS. 
2.2.2  RP-HPLC Fractionation 
 A 20 μL of the tryptic digestion solution was injected onto a C18 column (150 
mm x 4.6 mm, 5 μM size column particle, Alltech, Deerfield, IL) at a flow rate of 1 
mL/min.  The mobile phase A was purified water with 0.1% formic acid.  The mobile 
phase B was HPLC grade acetonitrile with 0.1% formic acid.  A linear gradient was 
used to elute the glycopeptides starting with a 5% B for 3 min.  This was followed by 
a linear increase to 40% B in 15 min, and held at 40% B for 15 min.  A linear increase 
to 95% B occurred for 20 minutes and held at 95% B for 3 min.  Fractions were 
collected every 1 min for 60 min.  The fractions were dried in a centrivap (Labconco 
Corporation, Kansas City, MO) before reconstituting with 10 μL of water for 
MALDI-TOF/TOF MS analysis.   
2.2.3  N-Deglycosylation 
 The HPLC glycopeptide fractions were first analyzed by MALDI-TOF/TOF 
and all fractions that contained glycopeptides were then deglycosylated using N-
glycosidase F or PNGase F (CalBioChem) with the protocol recommended by the 
manufacturer.  A 500 units/mL of PNGase F solution was prepared by adding 100 μL 
of deionized water to 50 units of PNGase F.  Approximately 3 μL of each 
glycopeptide fraction was deglycosyated by adding 3 μL of PNGase F with 9 μL of 
20 mM NH4HCO3 (pH=8) and incubated overnight at 37 °C.  The reaction was 
stopped the next day by heating the sample to 90 °C.  Any fractions that contained 
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glycopeptides from the rp-HPLC fractionation with MALDI-TOF/TOF were 
reanalyzed again with MALDI-TOF/TOF after deglycosylation. 
2.2.4  MALDI-TOF/TOF Analysis 
 The matrix was made with equal volumes of saturated solutions of DHB in 
50% ACN in water and CHCA in 50% ACN in water with 0.1% TFA.  The HPLC 
fractionated glycopeptides were spotted on a stainless steel MALDI plate and allowed 
to air-dry.  All MALDI MS and MS/MS experiments were collected by an Applied 
Biosystems 4700 Proteomics Analyzer mass spectrometer (Foster City, CA) in the 
positive reflectron ion mode.  The samples were irradiated with a 355 nm ND:YAG 
laser at 200 Hz.  The mass spectra was generated by averaging 3200 laser shots and 
optimized to provide the best signal-to-noise (S/N) ratio and resolution for each 
sample.   
2.2.5  HPLC/ESI-FTICR MS Analysis 
 The digested sample was analyzed using a hybrid linear ion-trap (LIT) Fourier 
Transform ion cyclotron mass spectrometer (LTQ-FTICR, ThermoElectron, San Jose, 
CA) that was coupled to a Dionex UltiMate capillary LC system (Sunnyvale, CA).  
Approximately 5 μL of the digested sample was injected into a C18 PepMap 300 
column (15 cm x 300 μm I.D., particle size 5 μm, 300 Å) at a flow rate of 5 μL/min.  
The mobile phases used for the elution of the glycopeptides were purified water with 
0.1% formic acid for mobile phase A and HPLC grade acetonitrile with 0.1% formic 
acid for mobile phase B.  A linear gradient was used to elute the glycopeptides 
starting with a 5% B for 3 min.  This was followed by a linear increase to 40% B in 
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15 min, and held at 40% B for 15 min.  A linear increase to 95% B occurred for 20 
minutes and held at 95% B for 3 min.  Fractions were collected every 1 min for 60 
min.  A full LTQ-FTICR MS1 scan within the mass range m/z 800-2000 were 
followed by three data-dependent MS/MS scans in the positive ion mode.  The data-
dependent scans for the three most intense ions from the MS1 data.  MS3 data was 
also acquired if a neutral loss of hexose or a HexNAc was detected in the MS2 scans.  
A spray voltage of 4.0 kV and the capillary temperature was set to 200 °C.  All the 
mass spectrometry data for this study was collected in collaboration with Dr. Eden 
Go, another member of the Desaire group.  
2.2.6  Data Analysis 
 These proteins were enzymatically cleaved using trypsin and separated using 
reverse phase high-performance liquid chromatography (rp-HPLC).  FTICR-MS and 
MALDI-TOF were the instrumentations used for the glycopeptide data analysis.  The 
analysis of the glycopeptide composition has been described previously.5, 6  Briefly, 
the glycopeptide compositions were assigned using two web-based programs:  
GlycoPep ID6 and GlycoPep DB5.  GlycoPep ID identifies for characteristic ions such 
as the Y1 ion [Peptide + 203 +H]+ that occur after collision-induced dissociation 
(CID).6   
 GlycoPep ID determines the number of N-linked glycosylation sites using the 
protein sequence along with the digestion methods such as the protelytic enzyme.6  A 
table of all possible peptides is generated with the glycosylation sites.  This table lists 
all possible theoretical peptides that can occur with the specific digestion methods 
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selected and is then compared to the experimental peak list from the MS2 data.6  The 
program matches characteristic ions that fall within the mass tolerance specified by 
the user.6  If the program matches more than one peptide, the user can repeat the 
search with a different characteristic ion or look manually at the spectrum to confirm 
the peptide portion.  Alternatively, both peptide possibilities could be considered in 
the next step, which is to determine the glycan portion using GlycoPep DB.   
 GlycoPep DB contains a database of 319 N-linked glycans that have been 
found in the literature.5  GlycoPep DB only uses biologically relevant glycans in 
assigning the carbohydrate portion of the glycopeptides.5  GlycoPep DB generates a 
list of possible glycopeptide compositions that fall within the range of the mass 
tolerance.5   
 Once the plausible glycopeptide compositions have been generated using both 
GlycoPep ID and GlycoPep DB, the user can confirm those assignments by manually 
checking the MS2 spectra for all of the peaks that have MS2 data by looking for 
cleavages of neutral losses of individual sugars and cleavages along the peptide 
backbone.   
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2.3  Results and Discussion 
 When comparing the same sites in the two different proteins, many of the 
peptides within these have the same glycan composition.  Out of the possible 29 N-
linked glycosylation sites on Con C and 24 possible N-linked glycosylation sites on 
VRC_C, ten were assigned for Con C with various high-mannose glycoforms and six 
were assigned for VRC_C with various high-mannose glycoforms shown in Table 1 
and Table 2 respectively.  The current data presented shows there are some 
similarities within the glycosylation sites between a consensus sequence and a wild-
type sequence.  However, this data is not complete and further analysis needs to be 
done to compare these two sequences further.   
 











Peptide Sequence Carbohydrate 
Composition 
2+ 1454.1570 1454.1276 20 LINCN185TSAITQACPK [Hex]5[HexNAc]2 
2+ 1535.1853 1535.1540 20 LINCN185TSAITQACPK [Hex]6[HexNAc]2 
2+ 1568.7205 1568.7181 15 LINCN185TSAITQACPK [Hex]3[HexNAc]4 
[Fuc]1 
2+ 1559.1140 1559.0858 18 GEFFYCN372TSK [Hex]9[HexNAc]2 
2+ 1478.0848 1478.0594 17 GEFFYCN372TSK [Hex]8[HexNAc]2 
2+ 1316.0281 1316.0066 16 GEFFYCN372TSK [Hex]6 [HexNAc]2 
2+ 1397.0546 1397.0330 15 GEFFYCN372TSK [Hex]7[HexNAc]2 
2+ 1532.1665 1532.1375 19 AMYAPPIAGN416ITCK [Hex]7[HexNAc]2 
2+ 1296.0548 1296.0418 10 EISN576YTDTIYR [Hex]5[HexNAc]2 
2+ 1605.1929 1605.1664 17 AMYAPPIAGN416ITCK [Hex]8[HexNAc]2 
2+ 1605.1974 1605.1664 19 AMYAPPIAGN416ITCK [Hex]8[HexNAc]2 
2+ 1686.2271 1686.1928 20 AMYAPPIAGN416ITCK [Hex]9[HexNAc]2 
2+ 1382.1437 1382.1080 26 LDIVPLNEN176NSYR [Hex]5[HexNAc]2 
2+ 1529.1542 1529.1153 25 N145CSFN149ITTELR [Hex]8[HexNAc]2 
2+ 1476.6749 1476.6443 21 SN422ITGLLLTR [Hex]9[HexNAc]2 
2+ 1395.6450 1395.6179 19 SN422ITGLLLTR [Hex]8[HexNAc]2 
2+ 1540.7130 1540.6679 29 LICTTAVPWN550SSWSN555K [Hex]5[HexNAc]2 
Table 1.  Glycopeptides of Con C with m/z from the peak list compared to the theoretical 
database mass and their mass errors.   
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Peptide Sequence Carbohydrate 
Composition 
2+ 1158.5632 1158.5330 26 TIIVHLN248K [Hex]6 [HexNAc]2 
2+ 1239.5927 1239.5594 27 TIIVHLN248K [Hex]7[HexNAc]2 
2+ 1077.5352 1077.5066 27 TIIVHLN248K [Hex]5[HexNAc]2 
2+ 1158.5657 1158.5330 28 TIIVHLN248K [Hex]6 [HexNAc]2 
2+ 1280.0540 1280.0178 28 N110CSFN114TTTEIR [Hex]5[HexNAc]2 
2+ 1418.0923 1418.0439 34 GEFFYCN344TTR [Hex]7[HexNAc]2 
2+ 1499.1262 1499.0703 37 GEFFYCN344TTR [Hex]8[HexNAc]2 
2+ 1580.1622 1580.0967 41 GEFFYCN344TTR [Hex]9[HexNAc]2 
2+ 1256.0236 1255.9911 26 GEFFYCN344TTR [Hex]5[HexNAc]2 
2+ 1337.0559 1337.0175 29 GEFFYCN344TTR [Hex]6 [HexNAc]2 
2+ 1174.9998 1174.9647 30 GEFFYCN344TTR [Hex]4[HexNAc]2 
2+ 1276.5404 1276.5044 28 GEFFYCN344TTR [Hex]4[HexNAc]3 
2+ 1524.1969 1524.1400 37 AMYAPPIAGN387ITCK [Hex]7[HexNAc]2 
2+ 1605.2278 1605.1664 38 AMYAPPIAGN387ITCK [Hex]8[HexNAc]2 
2+ 1686.2626 1686.1928 41 AMYAPPIAGN387ITCK [Hex]9[HexNAc]2 
2+ 1710.8176 1710.7143 60 AMYAPPIAGN387ITCK [Hex]5 [HexNAc]4 
[NeuNAc]1 
2+ 1394.6696 1394.6282 30 SN393ITGLLLVR [Hex]8[HexNAc]2 
2+ 1313.6399 1313.6018 29 SN393ITGLLLVR [Hex]7[HexNAc]2 
2+ 1475.7002 1475.6546 31 SN393ITGLLLVR [Hex]9[HexNAc]2 
2+ 1151.5769 1151.5490 24 SN393ITGLLLVR [Hex]5[HexNAc]2 
2+ 1232.6073 1232.5754 26 SN393ITGLLLVR [Hex]6 [HexNAc]2 
Table 2.  Glycopeptides of VRC_C with m/z from the peak list compared to the theoretical 
database mass and their mass errors 
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 While a significant number of glycoforms have been identified, it is likely that 
many more glycoforms are present that have not yet been characterized.  One 
problem with the current data set is that high mannose glycans were predominately 
found between these two proteins, yet it is likely that several hybrid and complex 
glycans are also attached to these peptides.  The hybrid and complex N-linked 
glycans are more difficult to analyze than the high-mannose N-linked glycans.  This 
is due to the increased difficulty in finding the characteristic Y1 ion in the MS2 
spectra of the hybrid and complex glycans.  The characteristic Y1 ion for a high-
mannose glycans in a linear ion trap can be seen as the base peak whereas the 
characteristic Y1 ion for a hybrid or complex glycan is not seen as the base peak.7  
This can be attributed to the ease at which fucose and the 1-4 linked HexNAc can be 
cleaved, compared to the glycosidic cleavages of high-mannose glycans.7  The data 
analysis steps for assigning glycopeptides with unprocessed glycans, shown in Fig. 
2.4, is accomplished by observing sequential losses of sugar moieties within the 
overall glycans profile.  This data analysis method was not successful in assigning all 
of the possible N-linked sites.  The sequence coverage is not complete and not all of 
the glycopeptides were assigned.  It’s possible that some glycopeptides co-elute and 
better separation techniques can solve this problem.  Chapter three addresses the 
question of whether or not a better separation technique could provide better sequence 
coverage for glycopeptide analysis. 
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Fig. 2.4: Representative example MS data of an unprocessed glycoform of Con C (A) MS and (B) 
MS/MS spectra using HPLC/ESI-FTICR 
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2.4  Conclusion 
 Ten N-linked glycosylation sites were found on Con C and six N-linked 
glycosylation sites were found on VRC_C.  The remainder of the potential 
glycosylation sites were not able to be determined by HPLC/ESI-FTICR-MS or 
MALDI TOF/TOF MS.  Processed glycans were not seen in the spectra.  Another 
technique to aid in assigning processed and unprocessed glycans can be performed to 
enhance the coverage.   Also, by refining the chromatographic separation methods to 
further separate the unprocessed glycans from the processed glycans, more 
glycoforms may be detected.   
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Glycopeptide Separation Methods Using Asialofetuin 
3.1  Introduction 
 The analysis of glycopeptides in a proteolytic digest is problematic due to the 
presence of peptides along with glycopeptides in the sample.  Peptides ionize better 
than glycopeptides and would suppress the signal intensity of the glycopeptides if 
both are present in the sample.   
 A variety of methods have been proposed to isolate the glycopeptides within a 
peptide mixture.  Lectin-affinity chromatography can isolate glycoproteins with 
different carbohydrate types.1  This method is useful if the glycoforms are known on 
the glycopeptides.  Analysis of glycopeptides with an unknown variety of glycoforms 
would be problematic for this method.  Affinity separation using cellulose or 
Sepharose on glycopeptides from a peptide mixture is another method.  The affinity 
of the cellulose or Sepharose is dependent on the hydrogen bonding between the 
hydroxyl group of carbohydrates on cellulose or Sepharose and the glycopeptides.2  
High-performance anion-exchange (HPAE) chromatography with pulsed 
amperometric detection (PAD) has been used to separate oligosaccharides according 
to molecular size, sugar composition, and linkage of the monosaccharide units.3  This 
technique requires high concentrations of sodium hydroxide and sodium acetate, and 
these salts have to be removed before further analysis.4   
 Liquid chromatography has been extensively used in separation of glycans.5  
The study in this chapter investigates the separation efficiencies of three various 
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capillary columns (C18 column, porous graphite carbon column, and a zwitterionic 
hydrophilic interaction column) with three unique retention mechanisms, to 
selectively purify/enrich glycopeptides present in a peptide mixture.   
 Reverse-Phase High Performance Liquid Chromatography (rp-HPLC) is the 
conventional method for separation of glycopeptides after enzymatic digestion.6  
Silanes that possess alky chains (mainly C18) are the standard stationary phase for 
reverse-phase separation.  The stationary phase also contains polar alky groups to 
increase the retention of polar compounds.7  Polar embedded or polar end-capped 
groups have been used to improve separation efficiencies of highly polar 
compounds.8   
 Porous graphitized carbon (PGC) exhibit properties similar to reverse-phased 
columns, but they are able to retain more hydrophilic analytes and provide separation 
of structurally similar oligosaccharides.9  The retention mechanism for PGC is due to 
a combination of dispersive interactions or hydrophobic interactions and charge-
induced interactions.10-12  London dispersive interactions (as well as dipole-dipole and 
hydrogen bonding) between the analytes and the eluents increase the analytes’ 
retention to the graphite surface.13  Hydrophobic interactions between the analyte and 
the eluent will affect the retention for the graphite surface.  Repulsions between the 
hydrophilic eluent and non-polar segments of the analytes will increase retention of 
the analyte for the graphite surface.12, 13   
 Charge-induced interactions force polar groups on the analyte to be closer to 
the graphite surface, as shown in Fig. 3.1.10, 11, 14, 15  The flat surface reduces the 
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retention of highly structural and rigid analytes, which can only come in contact with 
the graphite surface with a portion of their own surface.11, 16  The molecular area of an 
analyte that is in contact with the graphite surface largely determines the strength of 
the interaction.10  Hence, planar molecules tend to come in contact with the graphite 
surface better than non-planar molecules and have a higher retention for the graphite 
surface than non-polar molecules.17   
 
 
Fig. 3.1:  Charge-induced interactions from polar groups of the analyte 
 
 Hydrophilic interaction liquid chromatography (HILIC) is similar to normal-
phase chromatography but distinguishes itself from normal-phase in that the mobile 
phases contain water-miscible solvents, whereas normal-phase chromatography uses 
non-water-miscible solvent buffers.18   
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 Interaction with the ZIC-HILIC stationary phase is based on a partitioning 
mechanism, with electrostatic interactions from the sulfonic group and quaternary 
ammonium group, as shown in Fig. 3.2.19, 20  The ZIC-HILIC surface has a zero net 
charge due to the 1:1 ratio of quaternary ammonium and sulfonic acid group.20  The 
stationary phases are very hydrophilic and easily absorb or imbibe water.5  Having a 
very hydrophilic stationary phase and a relatively hydrophobic mobile phase allows 
for the hydrophilic analytes to partition between the hydrophilic stationary phase and 
relatively hydrophobic bulk eluent.5, 18, 20  The order of elution is the opposite of 
reverse-phase chromatography; the hydrophilic compounds will be retained longer 
than hydrophobic compounds.18, 20  This makes a HILIC column an ideal tool for 
analysis of complex samples with poor retention towards reverse-phase 
chromatography.   
 
 
Fig. 3.2:  Stationary phase of ZIC-HILIC with partitioning mechanism and electrostatic 




 Since the retention of compounds is based on polar interactions, the retention 
of glycopeptides tends to increase with an increase in the length of the glycans chains, 
and the elution position may provide a rough indication of the glycans size.21   
 Asialofetuin was chosen in this experiment because its complete structure has 
been well studied.22-24  Fig. 3.3 shows three well characterized N-linked glycosylation 
sites in asialofetuin (residues at N99CS, N156DS, and N176GS) which make it ideal for 
distinguishing the capability of each column in separating glycopeptides from the 
peptide mixture.   
 
Fig. 3.3:  Protein sequence of asialofetuin.  N-linked glycosylation sites are in red. 
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3.2  Experimental Design 
 A capillary ZIC-HILIC column (150 mm x 0.3 mm I.D., particle size 5μm) 
was purchased from SeQuant (Umeå, Sweden).  Hypercarb (150 mm x 0.32 mm I.D., 
particle size 5 μm) and Aquasil C18 (150 mm x 0.32 mm I.D., particle size 5 μm) 
were purchased from Thermo Scientific (San Jose, CA)   
 Asialofetuin was purchased from Sigma-Aldrich (St. Louis, MO).  
Ammonium bicarbonate (NH4HCO3), trizma hydrochloride, trizma base, urea, 
ethylenediaminetetraacetic acid (EDTA), dithiothreitol (DTT), iodoacetamide (IAA), 
HPLC grade acetonitrile (ACN), and formic acid were all purchased from Sigma-
Aldrich (St. Louis, MO).  Proteomics grade trypsin was purchased from Promega 
(Madison, WI).  N-Glycosidase F (PNGase F) was acquired from Elizabethkingia 
meningosepticum and purchased from CalBioChem (San Diego, CA).  Purified water 
was obtained using a Millipore Direct-Q3 Water Purification System (Billerica, MA).   
 The overall experiment is shown in Fig. 3.4 with explanations in the 
proceeding paragraphs.   
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Fig. 3.4:  Experimental design of the asialofetuin glycopeptide analysis 
 
3.2.1  Protease digestion 
 Approximately 300 μg of asialofetuin protein was denatured in 25 mM 
ammonium hydrogen carbonate buffer with 4 M urea.  The proteins were reduced 
with 15 mM DTT for 1 hour and alkylated in the dark with 25 mM IAA for 1 hour, 
both at room temperature.  The sample was brought to a final concentration of 40 mM 
DTT to neutralize any excess IAA.  Ammonium hydrogen carbonate buffer was 
added to reduce the Urea concentration to 1 M.  Trypsin was added to digest the 
protein at a protein/enzyme ratio of 50:1 (wt/wt) in 37 °C for 18 hours.  The reaction 
was quenched by adding 1 μL of acetic acid for every 100 μL of total solution.  The 
final digested protein sample was analyzed by an online HPLC/ESI-FTICR-MS.   
 68
3.2.2  Glycopeptide Enrichment using capillary columns 
 A hybrid linear ion-trap (LIT) Fourier Transform ion cyclotron resonance 
mass spectrometer (LTQ-FTICR, ThermoElectron, San Jose, CA) was coupled to a 
Dionex UltiMate capillary LC system (Sunnyvale, CA).  The tryptic 
glycopeptide/peptide mixture was placed on a FAMOS well plate autosampler that is 
attached to the Dionex UltiMate capillary LC system.  For each run, 5 μL of the 
tryptic digest was injected onto one of the three various columns at a flow rate of 5 
μL/min.  The Aquasil C18 and Hypercarb used the same mobile phases.  The mobile 
phase A was purified water with 0.1% formic acid.  The mobile phase B was HPLC 
grade acetonitrile with 0.1% formic acid.  The HILIC column used 50% 
acetonitrile/10 mM ammonium acetate as the mobile phase A and 80% acetonitrile 
/10 mM ammonium acetate as the mobile phase B.  A linear gradient elution was used 
on all columns.  For the Aquasil C18 column, a linear gradient elution of 3% B for 
the first 3 minutes at a flow rate of 5 μL/min.  This was followed by a linear increase 
to 25% B in 12 minutes, then increased to 50% B for 15 minutes, then increased to 
75% B for an additional 20 minutes, and lastly to 95% B for 10 minutes.  The total 
elution time was 60 minutes.  For the Hypercarb column, a linear gradient of 3% B 
for the first 2 minutes at a flow rate of 5 μL/min.  This was followed by a linear 
increase to 25% B for 18 minutes, then an increase to 40% B for 10 minutes, followed 
by 50% B for 15 minutes, then 70% B for 5 minutes, then 82% B for the last 10 
minutes.  The total elution time was 60 minutes.  For the HILIC column, a linear 
gradient of 70% B for the first 5 minutes was used, then 55% B for 10 minutes, then 
 69
50% B for 15 minutes, then 40% B for 30 minutes, and lastly 32% B for 20 minutes.  
The total elution time was 80 minutes.  A short wash and a blank were run prior to 
each sample run to prevent any sample carryover.   
 A full LTQ-FTICR MS1 scan within the mass range m/z 800-2000 were 
followed by three data-dependent MS/MS scans in the positive ion mode.  The data-
dependent scans collected MS/MS data for the three most intense ions from the MS1 
data.  MS3 data was also acquired if a neutral loss of hexose or a HexNAc was 
detected in the MS2 scans.  A spray voltage of 4.0 kV and the capillary temperature 
was set to 200 °C.   
3.2.3  Data Analysis 
 The analysis of the glycopeptide composition has been described 
previously.25, 26  Briefly, the glycopeptide compositions were assigned using two web-
based programs:  GlycoPep ID25 and GlycoPep DB26.  GlycoPep ID identifies for 
characteristic ions such as the Y1 ion [Peptide + 203 +H]+ that occur after collision-
induced dissociation (CID).25   
 GlycoPep ID determines the number of N-linked glycosylation sites using the 
protein sequence along with the digestion methods such as the protelytic enzyme.25  A 
table of all possible peptides is generated with the glycosylation sites.  This table lists 
all possible theoretical peptides that can occur with the specific digestion methods 
selected and is then compared to the experimental peak list from the MS2 data.25  The 
program matches characteristic ions that fall within the mass tolerance specified by 
the user.25  If the program matches more than one peptide, the user can repeat the 
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search with a different characteristic ion or look manually at the spectrum to confirm 
the peptide portion.  Alternatively, both peptide possibilities could be considered in 
the next step, which is to determine the glycan portion using GlycoPep DB.   
 GlycoPep DB contains a database of 319 N-linked glycans that have been 
found in the literature.26  GlycoPep DB only uses biologically relevant glycans in 
assigning the carbohydrate portion of the glycopeptides.26  GlycoPep DB generates a 
list of possible glycopeptide compositions that fall within the range of the mass 
tolerance.26   
 Once the plausible glycopeptide compositions have been generated using both 
GlycoPep ID and GlycoPep DB, the user can confirm those assignments by manually 
checking the MS2 spectra for all of the peaks that have MS2 data by looking for 
cleavages of neutral losses of individual sugars and cleavages along the peptide 
backbone.  All of the plausible glycopeptide compositions generated by GlycoPep ID 
and GlycoPep DB were scrutinized manually by looking for neutral losses of glycans 
in the MS2 data.  MS1 data was also used to confirm the plausible glycopeptides.   
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3.3  Results and Discussion 
 The purpose of this study was to determine which column was the most 
advantageous in separating N-linked glycopeptides of asialofetuin from a peptide 
mixture, in order to better the separation methods and improve the glycosylation 
coverage for the HIV analysis.   
 In order to determine the glycopeptide compositions in asialofetuin, a 
proteolytic digest was performed using trypsin.  HPLC/ESI-FTICR MS and MS/MS 
experiments were chosen to investigate the separation capabilities of the three 
columns.  HPLC/ESI-FTICR MS was also chosen because the experiment can be 
performed online and would not require a RP-HPLC fractionation step if MALDI-
TOF MS and MS/MS was selected as the mass spectrometer.   
Glycopeptide Identification 
 Hypercarb, Aquasil C18, and ZIC-HILIC columns were used to elucidate the 
glycoforms on asialofetuin.  There are three N-linked glycosylation sites on 
asialofetuin (residues at N99CS, N156DS, and N176GS).  The Hypercarb column was 
able to separate the N156DS glycoform shown in Table 1.  The Aquasil C18 column 
was able to separate the N156DS and N176GS glycoforms shown in Table 2.  The ZIC-
HILIC column separated all three N-linked glycosylation sites on asialofetuin shown 















Peptide Sequence Carbohydrate 
Composition 
3+ 1243.5982 1243.5230 60.5 LCPDCPLLAPLN156DSR [Hex]6 
[HexNAc]5 
3+ 1121.8069 1121.8127 5.2 LCPDCPLLAPLN156DSR [Hex]5 
[HexNAc]4 
2+ 1864.8670 1864.7813 46.0 LCPDCPLLAPLN156DSR [Hex]6 
[HexNAc]5 
2+ 1682.2846 1682.2152 41.3 LCPDCPLLAPLN156DSR [Hex]6 
[HexNAc]5 
Table 1.  Hypercarb separation of glycopeptides in asialofetuin with m/z from the peak list compared to 
the theoretical database mass and their mass errors 
 










Peptide Sequence Carbohydrate 
Composition 
4+ 1160.6475 1160.5448 88.5 VVHAVEVALATFNAESN
176GSYLQLVEISR 
[Hex]5 [HexNAc]4 
3+ 1286.3039 1286.2218 63.8 KLCPDCPLLAPLN156DSR [Hex]6 [HexNAc]5 
3+ 1243.5855 1243.5235 50.0 LCPDCPLLAPLN156DSR [Hex]6 [HexNAc]5 
2+ 1682.3695 1682.2152 91.7 LCPDCPLLAPLN156DSR [Hex]5 [HexNAc]4 
3+ 1121.8960 1121.8127 74.3 LCPDCPLLAPLN156DSR [Hex]5 [HexNAc]4 
Table 2.  Aquasil C18 separation of glycopeptides in asialofetuin with m/z from the peak list compared 
to the theoretical database mass and their mass errors 
 
 










Peptide Sequence Carbohydrate 
Composition 
3+ 1547.1085 1547.0572 33.2 VVHAVEVALATFNAESN
176GSYLQLVEISR 
[Hex]5 [HexNAc]4 
3+ 1668.8517 1668.7679 50.2 VVHAVEVALATFNAESN
176GSYLQLVEISR 
[Hex]6 [HexNAc]5 
2+ 1864.8464 1864.7813 34.9 LCPDCPLLAPLN156DSR [Hex]6 [HexNAc]5 
3+ 1243.5528 1243.5235 23.6 LCPDCPLLAPLN156DSR [Hex]6 [HexNAc]5 
3+ 1682.2750 1682.2152 35.5 LCPDCPLLAPLN156DSR [Hex]5 [HexNAc]4 
3+ 1121.8361 1121.8127 20.9 LCPDCPLLAPLN156DSR [Hex]5 [HexNAc]4 
4+ 1415.6661 1415.6264 28.0 RPTGEVYDIEIDTLETTC
HVLDPTPLAN99CSVR 
[Hex]6 [HexNAc]5 
3+ 1765.5534 1765.4552 55.6 RPTGEVYDIEIDTLETTC
HVLDPTPLAN99CSVR 
[Hex]5 [HexNAc]4 
3+ 1286.3161 1286.2218 73.3 KLCPDCPLLAPLN156DSR [Hex]6 [HexNAc]5 
3+ 1164.5226 1164.5111 9.9 KLCPDCPLLAPLN156DSR [Hex]5 [HexNAc]4 
Table 3.  ZIC-HILIC separation of glycopeptides in asialofetuin with m/z from the peak list compared 
to the theoretical database mass and their mass errors 
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 The Aquasil C18 and the Hypercarb capillary columns are both reverse-phase 
chromatographic separation techniques, whereas the ZIC-HILIC capillary column is 
similar to a normal-phase chromatographic separation technique.  The ZIC-HILIC 
uses sulfoalkylbetaine functional groups as the stationary phase, which gives it better 
separation of highly polar compounds than common reverse-phase stationary phases 
employed with alkyl chains.7, 20  A charged polar stationary phase allows the ZIC-
HILIC column to attract water molecules from the mobile phase to form water-
enriched layers.7   
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3.4  Conclusion 
 Aquasil C18 and Hypercarb both used reverse-phase elution mechanism 
whereas the ZIC-HILIC is the opposite of reverse-phase chromatography.  The ZIC-
HILIC showed the best separation on asialofetuin glycopeptides and should be further 
studied in order to apply its partitioning mechanism to the study of HIV-1 envelope 
proteins.   
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4.1  Conclusion and future work 
 The ZIC-HILIC capillary column should be used as the separation method for 
the glycosylation analysis of the HIV-1 envelope proteins.  Another study should be 
performed on the ZIC-HILIC capillary column to separate glycopeptides from a 
peptide mixture with various buffer solvents and elution gradients in order to 
optimize the advantages of its unique partitioning mechanism.   
 
